Management Advisors Pipeline News Careers Publications Contact Us 中文


Wen Luo, PhD – Chief Executive Officer & Chief Scientific Officer


Dr. Luo has over 20 years of experience in the biomedical industry. Before founding Denovo Biopharma, Dr. Luo worked at Ligand Pharmaceuticals, where he led and participated in the research and development of multiple second-generation nuclear hormone receptor modulating drugs, worked on the molecular mechanism of hormone receptors, tissue and organ selectivity, and establishment of drug screening trials, and was responsible for formulating and implementing biomarker strategies for multiple drugs at different stages of development. While at Corvas, he was responsible for the development of new protease drug targets. At Incyte Genomics, Dr. Luo was involved in the management of at the time the world's largest proteome database LifeProt and worked on the research and development of new drug target genes and their splicing variants. He was engaged in the identification and development of new drug targets in the fields of cancer, immune diseases, and angiogenesis at Sugen. He served as a postdoctoral fellow at Howard Hughes Medical Institute of University of California, San Francisco. Dr. Luo holds a PhD in molecular biology and biochemistry from Indiana University.

Carrie Chen, CFA, CPA, MBA – Chief Financial Officer


Ms. Chen has more than 20 years of experience in the financial industry. Prior to joining Denovo Biopharma, Ms. Chen served as Asia-Pacific Leading Partner in Life-Science & Healthcare Industry at Deloitte, and worked in the investment banking department of CITIC Securities / CLSA (Hong Kong), as well as Deloitte New York and Taiwan. Ms. Chen holds an MBA in leveraged buyout and corporate strategy from the Wharton School of the University of Pennsylvania.

Xiao-Xiong Lu, PhD – Chief Technical Officer


Dr. Lu has more than 30 years of experience in the biomedical industry. Prior to joining Denovo Biopharma, Dr. Lu was Vice President of Technical Operations in Balance Therapeutics. Dr. Lu served as Assistant Vice President of CMC Technical Operations and General Manager of Greater China at Arena Pharmaceuticals. He also worked at Monsanto Company and its subsidiary Solutia Inc., and Ethyl Corporation. Dr. Lu holds a PhD in chemical engineering from University of Birmingham in the UK.

Michael Haller, PhD – Chief Business Officer


Dr. Haller has broad experience in business development and alliance management, finance, drug development, and corporate and product strategy, currently leading the Business Development and US Finance and Accounting teams at Denovo Biopharma.  Prior to Denovo, he was Chief Business Officer, responsible for business development and finance and accounting, at Peloton Therapeutics. As Vice President of Business Development and Alliance Management at Ligand Pharmaceuticals, Dr. Haller was responsible for out-licensing activities and managing Ligand’s numerous alliances.  Prior to Ligand, he was Senior Vice President of Strategic Partnerships at Anaphore (now Bird Rock Bio), where he managed Anaphore’s research and development partnership with Mitsubishi Tanabe Pharma Corporation and shaped Anaphore’s corporate strategy and operations.  He joined Anaphore from Halozyme Therapeutics, which he helped grow into a $1B market cap company, directed key alliances with Roche and Baxter Healthcare from deal signing and early preclinical and CMC activities through registration submissions, and headed the company’s drug delivery franchise.   Prior to Halozyme, Dr. Haller was a McKinsey & Company management consultant focusing on complex health care issues for a number of Fortune 500 companies.  Dr. Haller has published several peer-reviewed articles, presented at numerous scientific conferences, and is co-inventor on multiple patents.  Dr. Haller earned his PhD in Biomedical Engineering from The Johns Hopkins University School of Medicine, his MS in Chemical Engineering from Cornell University and his BS in Biomedical Engineering from The Johns Hopkins University.

About Us

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Network with Us

LI-In-Bug.pngFollow Us

Contact Us